US EditionPublished • loading... • Updated
This Top Dividend Stock Could Achieve a Major Milestone This Year. Is It a Buy?
Summary by The Motley Fool
1 Articles
1 Articles
This Top Dividend Stock Could Achieve a Major Milestone This Year. Is It a Buy?
Key PointsJohnson & Johnson could become the second biopharma company to achieve $100 billion in annual sales.The healthcare leader has a robust and diversified business that can support its dividend program. 10 stocks we like better than Johnson & Johnson › Johnson & Johnson (NYSE: JNJ), a leading healthcare giant, has been around for over 100 years and has achieved a lot in its long and storied history. The stock has also delivered solid retur…
·Alexandria, United States
Read Full ArticleCoverage Details
Total News Sources1
Leaning Left1Leaning Right0Center0Last UpdatedBias Distribution100% Left
Bias Distribution
- 100% of the sources lean Left
100% Left
L 100%
Factuality
To view factuality data please Upgrade to Premium
